Trivalent chromium versus synthetic and/ or biological DMARDs ( DrugBank: Chromium )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05545020 (ClinicalTrials.gov) | December 25, 2022 | 9/9/2022 | Trivalent Chromium Treatment for Rheumatoid Arthritis | Trivalent Chromium as a Treatment for Rheumatoid Arthritis Patients | Rheumatoid Arthritis | Drug: Trivalent chromium versus synthetic and/ or biological DMARDs | Alexandria University | NULL | Recruiting | 18 Years | 80 Years | All | 60 | Phase 2/Phase 3 | Egypt |